Evidence map›Paper›PMID 21543341›Full record

ArticleCancer prevention research (Philadelphia, Pa.)2011

Back to the future: mechanism-based, mutation-specific combination chemoprevention with a synthetic lethality approach.

Frank L Meyskens, Eugene W Gerner

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer prevention research (Philadelphia, Pa.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Mitigating the risk of radiation-induced cancers: limitations and paradigms in drug development.Journal of radiological protection : official journal of the Society for Radiological Protection · 2014
    Review
  3. Gut microbes, diet, and cancer.Cancer treatment and research · 2014
    Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Frank L MeyskensDepartment of Medicine, Chao Family Comprehensive Cancer Center, University of California, Irvine, California, USA. flmeyske@uci.edu
Eugene W Gerner

Funding

SPORE in Gastrointestinal CancerP50CA095060 · NCI · UNIVERSITY OF ARIZONA · PI GERNER, EUGENE W · 2002 to 2012
$25.3M
Prevention of APC-Dependent Intestinal CarcinogenesisR01CA123065 · NCI · UNIVERSITY OF ARIZONA · PI GERNER, EUGENE W · 2007 to 2011
$1.6M
NCI NIH HHS P50 CA095060NCI NIH HHS R01 CA123065
6 · The paper itself

Abstract

There is an increasing recognition that the mutations accompanying carcinogenesis may provide a window of therapeutic advantage designated synthetic lethality, an example of which is reported in this issue of the journal by Huang and colleagues (beginning on page 666). First discovered and studied in yeast, synthetic lethality has basic principles that have encouraged its development for treatment and now prevention in animal models of human cancer, especially malignancies refractory to standard approaches. The pros and cons of this approach and challenges in implementing it clinically are discussed.

Indexed as

Genes, LethalApoptosisApoptosis Regulatory ProteinsBiomimeticsHumansIntracellular Signaling Peptides and ProteinsLung NeoplasmsMitochondrial ProteinsMutationProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)ras ProteinsTNF-Related Apoptosis-Inducing LigandApoptosis Regulatory ProteinsDIABLO protein, humanIntracellular Signaling Peptides and ProteinsKRAS protein, humanMitochondrial ProteinsProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)ras ProteinsTNF-Related Apoptosis-Inducing LigandTNFSF10 protein, human

Identifiers

PMID21543341
PMCPMC3574813

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.